Abstract

A review of the studies presented at the SABCS 2022 conference on the treatment of breast cancer (BC) has been carried out; 16 of the most exciting and significant works reported at oral or poster sessions have been identified. Data from large randomized and population-based studies were presented, including TAM-01 (the role of adjuvant therapy with 5 mg tamoxifen for in situ cancer), six studies on the surgical treatment of early breast cancer, including a meta-analysis to assess the effect of surgery extent on overall survival, a comparison of the results of targeted lymph node dissection and biopsy of sentinel lymph nodes in patients after neoadjuvant systemic therapy, an analysis of the local relapse rate after breast-conserving surgery in patients with multicentric breast cancer, as well as the effect of carrier status of pathogenic variants of mutations in the ATM, BRCA1, BRCA2, CHEK2 and PALB2 genes on the occurrence of cancer of the contralateral breast. Among the systemic therapy studies, the 10-years results of APT trial, Peony trial were presented, as well as the results of the TMC analysis on the various roles of carboplatin addition in neoadjuvant chemotherapy regimens in patients younger and older than 50 years with triple-negative breast cancer, randomized clinical studies on the escalation of adjuvant endocrine therapy in high relapse risk groups (MonarchE and SWOG S1207), as well as new data on cognitive dysfunction after chemotherapy in patients in the RxPONDER trial. Also noteworthy are the reviews of treatment in special clinical situations: the first results of the POSITIVE trial (an assessment of the oncological and obstetric outcomes of interruption of adjuvant endocrine therapy for conception), an analysis of the mortality of males with breast cancer over the past 20 years, as well as an analysis of the methylmalonic acid effect on senile weakness in patients with early breast cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call